Jefferies Financial Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Jefferies Financial Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,565	Closed	-$1.35M	–	2111
2023 Q1	$1.35M	Buy	+12,565	New	+$1.45M	0.01%	783

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Jefferies Financial Group's RXDX Position: Q2 2023 in Review

Jefferies Financial Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 12,565 shares — an estimated $1.35M sold.

Jefferies Financial Group first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $1.35M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Jefferies Financial Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jefferies Financial Group sold 12,565 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.35M.
Jefferies Financial Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Jefferies Financial Group's Prometheus Biosciences, Inc. Common Stock position peaked at $1.35M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Jefferies Financial Group's 13F filing for Q2 2023, filed 14 Aug 2023.